<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659214</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180003</org_study_id>
    <secondary_id>2018-A01561-54</secondary_id>
    <nct_id>NCT03659214</nct_id>
  </id_info>
  <brief_title>Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults</brief_title>
  <acronym>ORK-AJA</acronym>
  <official_title>Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VERTEX Pharmaceutical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to evaluate the psychological reshuffle induced by ORKAMBI. The
      particular focus of this study is the consequence of its introduction on anxiety, depression,
      quality of life and adherence to all cystic fibrosis (CF) treatment. To answer this question
      investigators will monitor the psychological function of CF adolescents and young adults
      treated with ORKAMBI and compare them to CF adolescents and young adults not treated with
      ORKAMBI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction of KALYDECO then ORKAMBI, as a personalized medicine in the therapeutic strategy
      of Cystic Fibrosis (CF) may deeply modify the prognosis of patients with CF. These approaches
      realize the dream of short-circuiting the molecular mechanism of the disease and therefore
      opens the perspective of an extended and functional survival. It suddenly offers the
      possibility of a completely new future to the patient and his family, and therefore must
      deeply impact on the psychological function of all involved. Moreover, those new therapies
      may also modify the adherence to CF basic treatment, as it brings a new feeling of good
      health and the hope of a longer life. For that reason there is a need to investigate
      modifications of the psychological state of mind induced by the treatment with ORKAMBI in CF
      adolescents and young adults.

      This project aims to understand the psychological impact and to study the consequences of the
      introduction of ORKAMBI on adherence to CF treatment, anxiety, depression and quality of
      life.

      To answer this question, investigators will evaluate the psychological function of
      adolescents and young adults, aged 12 to 20 years, with CF treated with ORKAMBI, and compare
      it to other adolescents and young CF adults not treated with ORKAMBI.

      This is a cohort prospective study, with a 1 year follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score of Generalized Anxiety Disorder-7 questionnaire (GAD-7)</measure>
    <time_frame>24 months</time_frame>
    <description>to assess the impact on Anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score of Patient Health Questionnaire-9 (PHQ-9 )</measure>
    <time_frame>24 months</time_frame>
    <description>To assess the impact on Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of Cystic Fibrosis Questionnaire 14+ (CFQ 14+)</measure>
    <time_frame>24 months</time_frame>
    <description>Disease-specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms (Quality of Life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRERD Scale</measure>
    <time_frame>24 months</time_frame>
    <description>The 6 items are assessed using a YES/NO answer .The scale was validated in patients with chronic disease to assess medication adherence</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Treated group</arm_group_label>
    <description>Patients with proven CF (sweat-test &gt; 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Answering 4 questionnaires : anxiety, depression, quality of life and adherence</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Treated group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CF Center patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treated group: Patients with proven CF (sweat-test &gt; 60 mEq, 2 DF508 CF causing
             mutations, 12 to 20 years, and treated with ORKAMBI

          -  Control group: Patients not carrying 2 DF508 CF causing mutations, not treated with
             ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P
             or G1349D mutation or treated with Kalydeco

        Exclusion Criteria:

          -  Transplanted patients

          -  Patients younger than 12 years

          -  Patients older than 20 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya KIRSZENBAUM, Psychologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya KIRSZENBAUM, Psychologist</last_name>
    <phone>+33 (0)1 44 38 15 97</phone>
    <email>maya.kirszenbaum@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prissile BAKOUBOULA, PhD</last_name>
    <phone>+33 (0)1 71 19 64 94</phone>
    <email>prissile.bakouboula@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pneumology -CRCM - Necker - Enfants maladies Hospital (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya KIRSZENBAUM, MsD</last_name>
      <phone>+33 (0)1 44 38 15 97</phone>
      <email>maya.kirszenbaum@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pendleton DA, David TJ. The compliance conundrum in cystic fibrosis. J R Soc Med. 2000;93 Suppl 38:9-13. Review.</citation>
    <PMID>10911813</PMID>
  </reference>
  <reference>
    <citation>Bucks RS, Hawkins K, Skinner TC, Horn S, Seddon P, Horne R. Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs. J Pediatr Psychol. 2009 Sep;34(8):893-902. doi: 10.1093/jpepsy/jsn135. Epub 2009 Feb 5.</citation>
    <PMID>19196850</PMID>
  </reference>
  <reference>
    <citation>Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health. 2006 Jan;38(1):13-7.</citation>
    <PMID>16387243</PMID>
  </reference>
  <reference>
    <citation>Butner J, Berg CA, Osborn P, Butler JM, Godri C, Fortenberry KT, Barach I, Le H, Wiebe DJ. Parent-adolescent discrepancies in adolescents' competence and the balance of adolescent autonomy and adolescent and parent well-being in the context of Type 1 diabetes. Dev Psychol. 2009 May;45(3):835-49. doi: 10.1037/a0015363.</citation>
    <PMID>19413435</PMID>
  </reference>
  <reference>
    <citation>Arias Llorente RP, Bousoño García C, Díaz Martín JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros. 2008 Sep;7(5):359-67. doi: 10.1016/j.jcf.2008.01.003. Epub 2008 Mar 4.</citation>
    <PMID>18304896</PMID>
  </reference>
  <reference>
    <citation>Marciel KK, Saiman L, Quittell LM, Dawkins K, Quittner AL. Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatr Pulmonol. 2010 Feb;45(2):157-64. doi: 10.1002/ppul.21164.</citation>
    <PMID>20054860</PMID>
  </reference>
  <reference>
    <citation>Blackwell LS, Marciel KK, Quittner AL. Utilization of patient-reported outcomes as a step towards collaborative medicine. Paediatr Respir Rev. 2013 Sep;14(3):146-51. doi: 10.1016/j.prrv.2013.04.003. Epub 2013 May 27.</citation>
    <PMID>23721854</PMID>
  </reference>
  <reference>
    <citation>Girerd X, Radauceanu A, Achard JM, Fourcade J, Tournier B, Brillet G, Silhol F, Hanon O. [Evaluation of patient compliance among hypertensive patients treated by specialists]. Arch Mal Coeur Vaiss. 2001 Aug;94(8):839-42. French.</citation>
    <PMID>11575214</PMID>
  </reference>
  <reference>
    <citation>Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.</citation>
    <PMID>16717171</PMID>
  </reference>
  <reference>
    <citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.</citation>
    <PMID>11556941</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Orkambi</keyword>
  <keyword>Adherence</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Depression</keyword>
  <keyword>Psychology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

